What is Global Blood Pressure Disorders Drug Market?
The Global Blood Pressure Disorders Drug Market is a vast and complex sector of the pharmaceutical industry that focuses on the development, production, and distribution of medications designed to manage and treat various blood pressure disorders. These disorders, which include conditions like hypertension (high blood pressure), hypotension (low blood pressure), and pulmonary hypertension (high blood pressure in the arteries of the lungs), can have serious health implications if left untreated. The market is driven by a combination of factors, including the increasing prevalence of these disorders worldwide, advancements in drug development and medical technology, and the growing awareness and understanding of these conditions among the general public. The market encompasses a wide range of drugs, each with its own unique mechanism of action and therapeutic benefits.
Diuretics, Angiotensin Converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (ARBs), Others in the Global Blood Pressure Disorders Drug Market:
The Global Blood Pressure Disorders Drug Market is segmented based on the type of drugs used to treat these conditions. These include Diuretics, Angiotensin Converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (ARBs), and others. Diuretics, also known as water pills, work by helping the kidneys remove excess water and salt from the body, thereby reducing blood volume and lowering blood pressure. ACE inhibitors and ARBs, on the other hand, work by blocking the action of certain chemicals that tighten the blood vessels, allowing blood to flow more smoothly and the heart to pump more efficiently. Other drugs used in the treatment of blood pressure disorders include beta blockers, calcium channel blockers, and vasodilators, each with their own unique mechanisms of action.
Hypertension, Hypotension, Pulmonary Hypertension in the Global Blood Pressure Disorders Drug Market:
The drugs in the Global Blood Pressure Disorders Drug Market are used to manage and treat a variety of conditions. Hypertension, or high blood pressure, is a common condition that affects millions of people worldwide. If left untreated, it can lead to serious health complications such as heart disease and stroke. Hypotension, or low blood pressure, while less common, can also have serious health implications, including dizziness, fainting, and in severe cases, shock. Pulmonary hypertension is a type of high blood pressure that affects the arteries in the lungs and the right side of the heart. It is a serious condition that can lead to heart failure if not properly managed. The drugs used to treat these conditions work by either lowering high blood pressure or raising low blood pressure to healthy levels.
Global Blood Pressure Disorders Drug Market Outlook:
Looking at the market outlook, the global pharmaceutical market, which includes the Global Blood Pressure Disorders Drug Market, is projected to reach a value of 1475 billion USD by 2022, growing at a compound annual growth rate (CAGR) of 5% over the next six years. This growth is driven by a variety of factors, including the increasing prevalence of chronic diseases, advancements in drug development and medical technology, and the growing global population. In comparison, the chemical drug market, which encompasses a wide range of drugs used in the treatment of various conditions, is expected to grow from 1005 billion USD in 2018 to 1094 billion USD by 2022. This growth is driven by similar factors, including the increasing demand for effective and affordable medications, advancements in chemical drug development, and the growing global population.
| Report Metric | Details |
| Report Name | Blood Pressure Disorders Drug Market |
| CAGR | 5% |
| Segment by Type |
|
| Segment by Application |
|
| By Region |
|
| By Company | A1M Pharma AB, Acceleron Pharma Inc, Ache Laboratorios Farmaceuticos SA, Actelion Pharmaceuticals Ltd, Aerogen Ltd, Anavex Life Sciences Corp, AnGes Inc, Arena Pharmaceuticals Inc, Ascendia Pharmaceuticals LLC, Ascendis Pharma A/S, AVEO Pharmaceuticals Inc, Bayer AG, Bial - Portela & Ca SA, Bioblue Technologies Inc, Biogen Inc, Biolab Farmaceutica Ltda, BioRestorative Therapies Inc, Boryung Pharmaceutical Co Ltd, Bristol-Myers Squibb Co, Camurus AB, Capricor Therapeutics Inc, Celsion Corp, Celtaxsys Inc, Chiesi Farmaceutici SpA, Chong Kun Dang Pharmaceutical Corp, Chugai Pharmaceutical Co Ltd, CJ HealthCare Corp, Complexa Inc, Corion Biotech Srl |
| Forecast units | USD million in value |
| Report coverage | Revenue and volume forecast, company share, competitive landscape, growth factors and trends |
